181 related articles for article (PubMed ID: 36119086)
21. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
22. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
[TBL] [Abstract][Full Text] [Related]
23. The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma.
Chang SJ; Chao CT; Kwan AL; Chai CY
Pathol Oncol Res; 2022; 28():1610230. PubMed ID: 35570844
[No Abstract] [Full Text] [Related]
24. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
25. Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature.
Zhang C; Guo L; Su Z; Luo N; Tan Y; Xu P; Ye L; Tong S; Liu H; Li X; Chen Q; Tian D
Front Cell Dev Biol; 2021; 9():717601. PubMed ID: 34650972
[TBL] [Abstract][Full Text] [Related]
26. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
27. Correlation of AIF-1 Expression with Immune and Clinical Features in 1270 Glioma Samples.
Rao M; Yang Z; Huang K; Liu W; Chai Y
J Mol Neurosci; 2022 Feb; 72(2):420-432. PubMed ID: 34939148
[TBL] [Abstract][Full Text] [Related]
28. Matrix Remodeling-Associated Protein 8 as a Novel Indicator Contributing to Glioma Immune Response by Regulating Ferroptosis.
Xu Z; Chen X; Song L; Yuan F; Yan Y
Front Immunol; 2022; 13():834595. PubMed ID: 35281049
[TBL] [Abstract][Full Text] [Related]
29. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Zeng F; Li G; Liu X; Zhang K; Huang H; Jiang T; Zhang Y
Oncologist; 2021 Aug; 26(8):e1460-e1469. PubMed ID: 33687124
[TBL] [Abstract][Full Text] [Related]
31. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
32. LGALS3 Is a Poor Prognostic Factor in Diffusely Infiltrating Gliomas and Is Closely Correlated With CD163+ Tumor-Associated Macrophages.
Hu WM; Yang YZ; Zhang TZ; Qin CF; Li XN
Front Med (Lausanne); 2020; 7():182. PubMed ID: 32528967
[No Abstract] [Full Text] [Related]
33. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
34. CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including Glioma.
Tanaka S; Ohgidani M; Hata N; Inamine S; Sagata N; Shirouzu N; Mukae N; Suzuki SO; Hamasaki H; Hatae R; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Iwaki T; Hosoi M; Iihara K; Mizoguchi M; Kato TA
Front Immunol; 2021; 12():670131. PubMed ID: 34267749
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma.
Zeng Y; Tan P; Ren C; Gao L; Chen Y; Hu S; Tang N; Chen C; Du S
Front Genet; 2022; 13():795844. PubMed ID: 35734424
[TBL] [Abstract][Full Text] [Related]
36.
Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
Front Immunol; 2021; 12():659659. PubMed ID: 33936093
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
[TBL] [Abstract][Full Text] [Related]
38. Up-Regulation of Long Non-Coding RNA AB073614 Predicts a Poor Prognosis in Patients with Glioma.
Hu L; Lv QL; Chen SH; Sun B; Qu Q; Cheng L; Guo Y; Zhou HH; Fan L
Int J Environ Res Public Health; 2016 Apr; 13(4):433. PubMed ID: 27104549
[TBL] [Abstract][Full Text] [Related]
39. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated macrophages related signature in glioma.
Wang LJ; Xue Y; Lou Y
Aging (Albany NY); 2022 Mar; 14(6):2720-2735. PubMed ID: 35332109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
